Genome-scale T cell activity array and methods of use thereof

Patent metadata

Field	Value
Publication number	US-10895569-B2
Application number	US-201615767673-A
Country	US
Kind code	B2
Filing date	Oct 11, 2016
Priority date	Oct 14, 2015
Publication date	Jan 19, 2021
Grant date	Jan 19, 2021

Abstract

The present invention provides Genome-Scale T Cell Activity Arrays (GS-TCAA), as well as methods of making these arrays and methods of using them to identify immune modulators.

First claim

We claim:

1. A Genome-Scale T Cell Activity Array (GS-TCAA), comprising
a solid support structure comprising a plurality of wells wherein each of said plurality of wells comprises:
a first cell that expresses a membrane associated anti-CD3 antibody, or antigen-binding fragment thereof, wherein said first cell has been transfected with a cDNA library encoding a plurality of human membrane genes in a manner that allows the display on said first cell of a protein encoded by one of said plurality of human membrane genes;
a second cell that expresses a receptor on the cell surface and a reporter gene;
wherein interaction between said receptor and said anti-CD3 antibody, or antigen-binding fragment thereof, provides a primary signal and stimulates the activity of said second cell line, and
wherein an increase in the expression level of said reporter gene indicates that said displayed protein encoded by one of said plurality of human membrane genes acts as a stimulatory co-signaling molecule and stimulates the activity of said second cell line, and wherein a decrease in the expression level of said reporter gene indicates that said displayed protein encoded by one of said plurality of human membrane genes acts as an inhibitory co-signaling molecule and inhibits the activity of said second cell line.

2. The array of claim 1 , wherein the solid support structure is a multi-well plate.

3. The array of claim 1 , wherein the first cell is a human 293T cell; or a human 293T.2A cell which expresses an immune-related adaptor.

4. The array of claim 3 , wherein the immune-related adaptor is selected from the group consisting of DAP10, DAP12, FcRγ and CD3E.

5. The array of claim 1 , wherein the second cell is an immune cell.

6. The array of claim 5 , wherein the immune cell is a myeloid-derived suppressor cell (MDSC); or the immune cell is a T cell.

7. The array of claim 1 , wherein the reporter gene is contained in a DNA construct selected from the group consisting of a cytotoxicity related reporter construct, an apoptosis related reporter construct and a proliferation related reporter construct.

8. The array of claim 1 , wherein said plurality of human membrane genes comprises a gene selected from a receptor gene, an immunoglobulin gene, a transporter gene and a signaling gene; said plurality of human membrane genes comprises about 1,000-7,000 genes; said plurality of human membrane genes comprises about 2,000-5,000 genes; or said plurality of human membrane genes comprises about 4,000-7,000 genes.

9. The array of claim 1 , wherein said activity of said second cell is selected from the group consisting of cell proliferation, cell suppression, cell exhaustion, cell apoptosis, and cytokine release from cells.

10. A method of making a Genome-Scale T cell Activity Array (GS-TCAA), the method comprising:
providing a solid support structure comprising a plurality of wells;
culturing a first cell that expresses a membrane associated anti-CD3 antibody, or antigen-binding fragment thereof, into each of said plurality of wells;
transfecting said first cell with a cDNA library encoding a plurality of human membrane genes in a manner that allows the display on said first cell of a protein encoded by one of said plurality of human membrane genes; and
co-culturing a second cell that expresses a receptor on the cell surface and a reporter gene into each of said plurality of wells, thereby preparing a Genome-Scale T cell Activity Array,
wherein interaction between said receptor and said anti-CD3 antibody, or antigen-binding fragment thereof, provides a primary signal and stimulates the activity of said second cell line, and
wherein an increase in the expression level of said reporter gene indicates that said displayed protein encoded by one of said plurality of human membrane genes acts as a stimulatory co-signaling molecule and stimulates the activity of said second cell line, and wherein a decrease in the expression level of said reporter gene indicates that said displayed protein encoded by one of said plurality of human membrane genes acts as an inhibitory co-signaling molecule and inhibits the activity of said second cell line.

11. The method of claim 10 , wherein the solid support structure is a multi-well plate.

12. The method of claim 10 , wherein the first cell is a human 293T cell; or a human 293T.2A cell which expresses an immune-related adaptor.

13. The method of claim 10 , wherein the second cell is an immune cell.

14. The array of claim 13 , wherein the immune cell is a myeloid-derived suppressor cell (MDSC); or a T cell.

15. The method of claim 10 , wherein the reporter gene is contained in a DNA construct selected from the group consisting of a cytotoxicity related reporter construct, an apoptosis related reporter construct and a proliferation related reporter construct.

16. A method of identifying an immune modulator, the method comprising:
providing the Genome-Scale T cell Activity Array (GS-TCAA) of claim 1 ;
allowing the expression of one of said plurality of human membrane genes in the first cell,
co-culturing the first cell and the second cell;
detecting the expression level of said reporter gene in the second cell; and
comparing the expression level of said reporter gene with the expression level of said reporter gene in a control second cell wherein the control second cell is co-cultured with a control first cell that has not been transfected with one of said plurality of human membrane genes,
wherein an increase in the expression level of said reporter gene indicates that said displayed protein encoded by one of said plurality of human membrane genes acts as a stimulatory co-signaling molecule and stimulates the activity of said second cell line, and wherein a decrease in the expression level of said reporter gene indicates that said displayed protein encoded by one of said plurality of human membrane genes acts as an inhibitory co-signaling molecule and inhibits the activity of said second cell line, thereby identifying said immune modulator.

17. The method of claim 16 , wherein said immune modulator is selected from the group consisting of FOLH1, FAS, IL3RA, CD248, THBD, B7.1, GJB1, OX40L, 4-1BBL and B7.2; or said immune modulator is selected from the group consisting of FLT1, CXCR6, SEMA6a, RHCE, FCRLA, TNFRSF19, SEC22b, B3GNT1, NFAM1, LY6 and GP1BA; or said immune modulator is selected from the group consisting of FLT1, SEMA6a, SEC22b and GP1BA.

18. The method of claim 16 , further comprising performing an assay selected from the group consisting of an in vitro functional assay, an in vivo assay, a receptor array assay, a bioinformatics assay, or a combination thereof.

19. The method of claim 18 , wherein the in vitro functional assay comprises
culturing said second cell expressing one of said plurality of human membrane genes and the membrane-associated anti-CD3 antibody, or antigen-binding fragment thereof, with a primary T cell; and
performing an in vitro functional assay selected from the group consisting of a proliferation assay, an apoptosis assay and a cytokine release assay.

Assignees

• Univ Yale

Inventors

• Chen Lieping
• Wang Jun

Classifications

• C40B40/02

  Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors · CPC title

• G01N2333/70532

  B7 molecules, e.g. CD80, CD86 · CPC title

• G01N33/505 Primary

  involving T-cells · CPC title

• G01N33/5023

  on expression patterns · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title